Search

everythinglearnresearchcommunity

for

Search:↓

A gene variant increases the risk of a type of hair loss by affecting hair protein production.

Poor response to topical immunotherapy in alopecia areata patients is linked to impaired cell responses.

Anti-DFS70 antibodies can help identify nonsystemic autoimmune conditions in SLE patients.

M-CSF-stimulated myeloid cells can cause alopecia areata in mice.

CT60 polymorphism might increase the risk of Alopecia Areata.

Atopic dermatitis may trigger alopecia areata, and early treatment can help prevent severe cases.

The model showed that immune system guardians and the cytokine interferon-γ are key in alopecia areata progression.

Hidradenitis suppurativa might be a type of autoinflammatory skin disease.

Cytotoxic T cells cause hair loss in chronic alopecia areata.

Chronic refractory alopecia areata has more skin-resident memory T cells, and JAK inhibitors may help reduce them.

Granulomatous Alopecia Areata is rare and may be caused by hair antigens or follicle destruction.

Certain blood markers, especially MLR, can help diagnose alopecia areata.

A 22-year-old with multiple autoimmune diseases needs a multidisciplinary treatment approach.

Atopic dermatitis and alopecia areata share immune and genetic factors, and targeted therapies may help both.

Many children with alopecia areata also have other autoimmune diseases.

COVID-19 can worsen autoimmune skin diseases and increase their occurrence.

Restoring hair follicle immune privilege may help treat alopecia areata.

Etanercept may not prevent alopecia areata from coming back.

Alopecia areata is influenced by genetics and immune system factors, and better understanding could improve treatments.

Malt1 protease is essential for regulatory T cell function and could be targeted to boost antitumor immunity.

Alopecia areata is caused by immune system issues, and JAK inhibitors might help treat it.

MCHR2 gene duplications may be linked to alopecia areata.

Immune cells and plasma proteins are linked to hair loss, suggesting new treatment options.

New medicines that block a specific pathway are showing promise for treating severe hair loss but need more testing for safety and effectiveness.

Targeting MIG and MCP-1 may help treat inflammation in alopecia areata.

The 3D skin model mimics pemphigus vulgaris and helps test treatments.

Higher CRHR1 levels in AA patients lead to increased inflammation.

Regulatory T cells help prevent autoimmunity and have potential for treating autoimmune diseases.

Reduced Stx17 expression may contribute to Alopecia Areata.